Cost-Effectiveness of Paricalcitol Versus Parathyroidectomy for Secondary Hyperparathyroidism to Chronic Kidney Disease in Mexico
نویسندگان
چکیده
منابع مشابه
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active vitamin D. Replacement with calcitriol, the active form of vitamin D, lowers PTH but often raise...
متن کاملLong-term outcomes following "presumed" total parathyroidectomy for secondary hyperparathyroidism of chronic kidney disease.
AIM The most efficacious surgical treatment for renal hyperparathyroidism is still subject of research. Considering its low incidence rate of long-term relapse, "presumed" total parathyroidectomy without autotrasplantation (TP) may be indicated for secondary hyperparathyroidism (2HPT) in patients with chronic kidney disease (CKD), not eligible for kidney transplantation. The aim of this study w...
متن کاملSecondary hyperparathyroidism in chronic kidney disease
Chronic kidney failure is much more common than people realize, and often goes undetected and undiagnosed until the disease is well advanced and k function decreases it affects many other systems of the body mainly the calcium phosphorous metabolism as the metabolism is mainly controlled by kidney in terms of absor of calcium phosphorus. Secondary hyperparathyroidism is usually found in patient...
متن کاملParicalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
Introduction Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. Methods This was a 6-month, investigator-initiated, multicen...
متن کاملParicalcitol for secondary hyperparathyroidism in renal transplantation.
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2013
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.08.2054